Transgene Biotek Share Price
2.74-0.03 (-1.08%)
-28.83% past 1 Year
Transgene Biotek Ltd (TBL) is engaged in manufacturing drugs for:New Drug Delivery System (NDDS)-Oral Delivery of Insulin Oral Delivery Hepatitis B Vaccine and Pegylation of Protein Drugs for Sustained Release.Biogeneries-Tacrolimus
Corporate filings & documents
Announcements
Newspaper Publication
3 weeks agoNewspaper Publication
3 weeks agoUnaudited Financial Results for the quarter ended 30th June 2026.
4 weeks agoUnaudited Financial Results for the quarter ended 30th June 2026.
4 weeks agoSub: Outcome of the Meeting of the Board of Directors held on August 07 2026.This has reference to our letter dated 22nd July 2026 Intimating the meeting of the Board of Directors of the Company.At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken:1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2025-26 subject to obtaining the necessary approval from the Registrar of Companies wherever applicable.
4 weeks agoSub: Outcome of the Meeting of the Board of Directors held on August 07 2026.This has reference to our letter dated 22nd July 2026 Intimating the meeting of the Board of Directors of the Company.At a meeting of the Board of Directors of the company held on 07th August 2026 the following decisions have been taken:1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2026.3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2025-26 subject to obtaining the necessary approval from the Registrar of Companies wherever applicable.
4 weeks agoTransgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby infom you that a meeting of the Board of Directors of Transgene Biotek Limited is scheduled to be held on Friday August 07 2026 inter alia to consider and approve the following matters: 1. To consider and approve the n-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30 2026.2. To consider and approve the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30h June 2026.3. To consider and approve seeking an extension of time for holding the Annual General Meeting (AGM) of the Company for the Financial Year 2025-26.4. To consider and approve the appointment of the internal auditor of the Company for financial year 2026-27.5. To transact such other business as may be required.
1 month agoTransgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby infom you that a meeting of the Board of Directors of Transgene Biotek Limited is scheduled to be held on Friday August 07 2026 inter alia to consider and approve the following matters: 1. To consider and approve the n-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended June 30 2026.2. To consider and approve the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30h June 2026.3. To consider and approve seeking an extension of time for holding the Annual General Meeting (AGM) of the Company for the Financial Year 2025-26.4. To consider and approve the appointment of the internal auditor of the Company for financial year 2026-27.5. To transact such other business as may be required.
1 month agoCompliance - 57(4)
1 month agoCompliance - 57(4)
1 month agoStatement of Deviation & Variation
1 month agoStatement of Deviation & Variation
1 month agoCompliance -57 (5)
1 month agoCompliance -57 (5)
1 month agoCompliances - Certificate under Reg. 74(5) of SEBI
1 month agoCompliances - Certificate under Reg. 74(5) of SEBI
1 month agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoNewspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.
3 months agoNewspaper Advertisement of Financial Results under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.
3 months agoAudited Financial Results
3 months agoAudited Financial Results
3 months agoThis has reference to our letter dated May 13 2026 The Board of Directors of the Company at their meeting held on May 29 2026 have resolved as follows:Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith the following: a) Audited Financial Results (Standalone and Consolidated) of the Company for the fourth quarter and financial year ended March 31 2026. b) Report of the Auditors on the Audited Financial Results both for (Standalone and Consolidated) financial statements for the financial year ended March 31 2026. c) Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for Consolidated and Standalone Financial Statements for the Financial Year ended March 31 2026.The meeting of the Board of Directors of the Company commenced at 11.00 AM and concluded at 11.30 AM.We kindly request you to take the above said on record.
3 months agoTransgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve To Consider and approve the Audited Financial Results (Standalone and consolidated) of the Company for the fourth quarter and financial year ended March 31 2026.
3 months agoTransgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve To Consider and approve the Audited Financial Results (Standalone and consolidated) of the Company for the fourth quarter and financial year ended March 31 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPLIANCE OFFICER AND COMPANY SECRETARY <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 13/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoNon-Applicability of Regulation 32(1) of SEBI.
4 months agoCompliance - 57 (4)
4 months agoNon-Applicability of Reg -57 (5) of SEBI LODR Regulations 2015.
4 months agoNon-Applicability of Reg -57 (5) of SEBI LODR Regulations 2015.
4 months agoCompliance certificate 7(3)
4 months agoCompliance certificate 7(3)
4 months agoCompliances Certificate under 74 (5) of SEBI
4 months agoCompliances Certificate under 74 (5) of SEBI
4 months agoClosure of Trading Window
5 months agoNewspaper Publication
6 months agoNewspaper Publication
6 months agoDear Sir/Madam This has reference to our letter dated January 28 2026.1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
6 months agoDear Sir/Madam This has reference to our letter dated January 28 2026.1) The Board has considered and approved the unaudited Consolidated & Stand-alone Financial Results of the company for the Quarter ended 31.12.2025 in accordance with the Indian Accounting Standards (IND-AS) as per Companies (Indian Accounting Standards) Rules 2015.2) Limited Review Report on the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended 31.12.2025 has also been approved.The meeting commenced at 11:00 a.m. and concluded at 11:45 a.m.
6 months agoGeneral Announcements
7 months agoTransgene Biotek Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve 1) To consider and approve the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 31st December 2025.2) To consider and approve the Limited Review Report (Standalone & Consolidated) for the quarter ended 31st December 2025.3) To transact such other business as may be required.
7 months agoStatement of Deviation & Variation
7 months agoCompliance -57 (5)
7 months agoCompliance -57 (4)
7 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Transgene Biotek Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195TG1990PLC011065</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: ANKITA JAIN <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: PRASAD CHOWDARY <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 12/01/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
7 months agoCompliances -Certificate under Reg.74(5) of SEBI.
7 months agoOUT COME RESULTS AND SCRUTINIZER REPORTS
8 months agoOUT COME OF VOTING AT 35TH AGM
8 months agoOutcome of 35th AGM
8 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Plot No. 69 & 70 Anrich Industrial Area I D A Bollaram Medak Dist Sangareddy Telangana PIN: 502325 Tel No: 040-65589499 Fax No: 08458 279755 Email: [email protected] Internet: www.transgenebiotek.com
Registrars
306,Right Wing Amruta Ville, Opp: Yashoda Hospital,Raj Bhavan Road,Somajiguda,Hyderabad 306, Right Wing, Amrutha Ville, Opp. Yasodha Hospital Raj Bhavan Road Somajiguda PIN: Tel No: +91-40-23374967/23370295 Fax No: +91-40-23370295 Email: [email protected] Internet: www.bigshareonline.com
Management
K Koteswara Rao, Chairman & Managing Director
K Koteswara Rao, Chairman & Managing Director
Sujana Kadiam, Non Executive Independent Director
Swetha Marri, Non Executive Independent Director
Santosh Kumar, Non Executive Independent Director
Ankita Jain, Company Secretary & Compliance Officer
Details
BSE 526139
NSE NULL
ISIN INE773D01018